Investor’s Business Daily (IBD) described BeOne Medicines (NASDAQ: ONC) as poised to hit “early buy points” in an article dated October 1, 2026. The available headline and search excerpt do not disclose the entry prices, chart pattern, or volume conditions, so they are not enough to confirm that ONC is at a buy point. What can be assessed from BeOne’s August 5 results is the business backdrop: second-quarter revenue grew 30%, led by BRUKINSA, while the company raised its full-year revenue outlook.
What does the early-buy-points headline establish?
IBD’s October 1, 2026 article frames BeOne as approaching multiple early buy points. The indexed material does not show the specific levels or technical criteria behind that framing. Treat it as IBD’s chart assessment, not as an independently verified entry signal or a recommendation to buy at a particular price.
Before acting on a technical setup, an investor would need the full IBD analysis or a current chart to identify the stated pattern, price levels, and volume conditions, then compare those with current market data and personal risk limits. The secondary SwingTradeBot listing likewise provides headline context, not the missing entry details.
What BeOne reported in Q2 2026
BeOne’s August 5, 2026 results release reported $1.705 billion in second-quarter revenue, up 30% from the year-earlier quarter. Product sales showed growth across its leading therapies and in-licensed medicines:
#1 Best Overall
| Revenue source | Q2 2026 sales | Year-over-year change |
|---|---|---|
| BRUKINSA, global | $1.2 billion | Up 31% |
| BRUKINSA, U.S. | $893 million | Up 31% |
| TEVIMBRA, global | $229 million | Up 18% |
| Amgen in-licensed products | $157 million | Up 25% |
These are company-reported Q2 figures; BRUKINSA’s global sales include its U.S. sales, so those two rows are not separate amounts to add together. The figures show that BRUKINSA was the largest reported product revenue source, while TEVIMBRA and in-licensed products also grew.
How to read earnings and revenue guidance
The same release reported diluted GAAP earnings of $2.05 per ADS and non-GAAP diluted earnings of $3.84 per ADS. It also reported $325.0 million in GAAP operating income and $503.0 million in adjusted operating income. GAAP and adjusted/non-GAAP measures use different accounting treatments and should not be compared as if they were identical.
Rank #2
- Ideal for Gifting
- Ideal for a bookworm
- Compact for travelling
BeOne raised its 2026 total revenue guidance to $6.6 billion–$6.8 billion. This is management’s full-year outlook, not revenue already earned or a guaranteed outcome. Comparing that outlook with the $1.705 billion recorded in Q2 alone cannot establish whether the company will meet guidance; the remaining quarters’ performance matters.
What business developments sit behind the results?
BeOne describes itself as a global oncology company focused on discovering and developing cancer treatments. Its results highlight BRUKINSA and TEVIMBRA alongside in-licensed products, while its August 2026 Form 10-Q describes a pipeline spanning hematology and solid tumors.
Recommended Free Tools
The filing also records a $300 million expansion of the company’s Hopewell, New Jersey clinical and commercial manufacturing and R&D center, announced July 23, 2026. It notes that the FDA granted accelerated approval on May 13, 2026, to BEQALZI (sonrotoclax) for adults with relapsed or refractory mantle cell lymphoma after at least two systemic therapy lines, including a BTK inhibitor. This is company-filing background; treatment decisions require current prescribing information and clinician guidance.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.What the business results can—and cannot—say about ONC stock
Revenue growth and a rising company outlook provide evidence about recent operating performance. They do not establish that the stock has a favorable technical entry, that it will reach an IBD buy point, or that its share price will rise. The chart claim and the financial results answer different questions.
Rank #4
BeOne is listed in the United States as ONC; the company’s investor overview also identifies HKEX 06160 and SSE 688235. Investors should match any quote or chart to the relevant listing and market before comparing prices or applying a technical level. For the U.S. ticker, the exact IBD levels and criteria remain unavailable in the indexed excerpt.
Quick Recap
Best Value
- It can be a gift option
- Comes with secure packaging
- Helpful in various ways
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
Quick wins for a faster PC:
Clear out junk files and repair common Windows errorsFree Scan →Fix the driver behind crashes, sound loss and screen glitchesFind Drivers →Repair Windows errors before they cause bigger problemsFix Now →
